Empowered Funds LLC Sells 10,120 Shares of Cencora, Inc. (NYSE:COR)

Empowered Funds LLC lowered its stake in Cencora, Inc. (NYSE:COR) by 13.3% during the fourth quarter, Holdings Channel reports. The firm owned 66,184 shares of the company’s stock after selling 10,120 shares during the period. Empowered Funds LLC’s holdings in Cencora were worth $14,870,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of COR. Dynamic Advisor Solutions LLC increased its position in shares of Cencora by 15.2% in the third quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company’s stock worth $262,000 after purchasing an additional 154 shares during the period. LVW Advisors LLC grew its position in Cencora by 14.2% in the third quarter. LVW Advisors LLC now owns 3,666 shares of the company’s stock valued at $825,000 after acquiring an additional 456 shares during the last quarter. Iowa State Bank bought a new position in Cencora in the third quarter valued at about $1,390,000. Livforsakringsbolaget Skandia Omsesidigt grew its position in Cencora by 33.7% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 27,375 shares of the company’s stock valued at $6,160,000 after acquiring an additional 6,900 shares during the last quarter. Finally, Valeo Financial Advisors LLC grew its position in Cencora by 5.0% in the third quarter. Valeo Financial Advisors LLC now owns 1,645 shares of the company’s stock valued at $370,000 after acquiring an additional 79 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.7 %

Shares of COR stock opened at $247.94 on Friday. The company has a market cap of $47.92 billion, a P/E ratio of 35.27, a PEG ratio of 1.49 and a beta of 0.49. The stock has a 50 day simple moving average of $238.94 and a two-hundred day simple moving average of $236.74. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.53 and a current ratio of 0.92. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Research analysts forecast that Cencora, Inc. will post 15.36 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s dividend payout ratio is 31.29%.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the transaction, the chairman now owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 73,187 shares of company stock worth $17,790,912. 10.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on COR shares. UBS Group lifted their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Wells Fargo & Company lifted their price target on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. Evercore ISI lifted their price target on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday. Barclays lifted their price target on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Robert W. Baird lifted their price target on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.